Financial PerformanceQ2 FY24 results showed revenues of $125,000, which were below the estimate of $170,000, and a pro-forma EPS of $(4.24) was impacted by a non-cash R&D charge.
Funding NeedsThe company is expected to need to raise additional funds by Q1 of FY25 due to a cash burn rate of $1-1.3 million per quarter.
Market UncertaintyThere is little insight into the malaria market at this time and the analyst awaits the company's findings from its pilot program.